DLBCL 免疫治疗中的巨噬细胞吞噬检查点：从 CD47 到 CD200 的证据成熟度框架

Macrophage phagocytosis checkpoints in DLBCL immunotherapy: an evidence-maturity framework from CD47 to CD200.

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

靶向 CD19、CD20 和 CD22 的床旁制备三特异性 CAR-T 细胞首次人体试验的安全性与临床结局

Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22.

CAR-T 细胞对比双特异性抗体治疗复发/难治性套细胞淋巴瘤：系统综述与荟萃分析

CAR T-cell vs bispecific antibodies in relapsed/refractory mantle cell lymphoma: a systematic review and meta-analysis.

CAR-T 细胞疗法相比双特异性抗体显示出更高的 CR 率，支持其作为 R/R MCL 有效三线治疗的作用。需要随机试验来证实这些发现。

Mosunetuzumab 联合 polatuzumab vedotin 治疗 BTK 抑制剂治疗后的复发/难治性 MCL：一项 2 期研究

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

大辩论：CAR-T 细胞疗法对比双特异性抗体治疗 B 细胞淋巴瘤

The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma.

开发串联犬 CAR-T 细胞以支持侵袭性 B 细胞淋巴瘤的比较研究

Development of tandem canine CAR T cells to enable comparative studies of aggressive B-cell lymphoma.

老年套细胞淋巴瘤：生物学风险分层、体能适应性策略与未满足需求

Mantle Cell Lymphoma in Geriatric Patients: Biologic Risk Stratification, Fitness-Adapted Strategies, and Unmet Needs.

CD19 CAR-T 细胞治疗滤泡性淋巴瘤后重度银屑病长期缓解

Long-term Remission of Severe Psoriasis Following CD19 CAR-T Cell Therapy for Follicular Lymphoma.

基于重复时间-事件模型的 Epcoritamab 剂量递增方案选择与优化以降低细胞因子释放综合征风险

Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.